CIK 0001314102
- Non-accelerated filer
- Smaller reporting company
EyePoint, Inc.
Sign in to watch- Ticker
- EYPT
- Exchange
- Nasdaq
- Industry
- Laboratory Analytical Instruments
- FY end
- Dec 31
- Incorporated
- DE
- Entity type
- Operating
- EIN
- 262774444
- Phone
- +1 617-926-5000
- Business address
- 480 PLEASANT STREET, SUITE C400, WATERTOWN, MA, 02472
- Former names
- EyePoint Pharmaceuticals, Inc., pSivida Corp., pSivida LTD
- Open-market buys, last 90 days
- $0
- in 0 filings
- Open-market sales, last 90 days
- $0
- in 0 filings
Shares bought or sold at a price by officers, directors and 10% owners (Form 4 codes P and S). Grants, option exercises and tax withholding aren't counted.
Reading 100 more Form 4s from the SEC; this list fills in as they're read.
| Date | Insider | Transaction | Shares | Price | Value | Owned after |
|---|---|---|---|---|---|---|
| 2021-06-22 | Godshall Douglas Evan Director | Grant or award · Stock Option (Right to Buy) | +11,000 | 11,000 | ||
| 2021-06-22 | GUYER DAVID R Director | Grant or award · Restricted Stock Units | +2,500 | 2,500 | ||
| 2021-06-22 | GUYER DAVID R Director | Grant or award · Stock Option (Right to Buy) | +11,000 | 11,000 | ||
| 2021-06-22 | Landis John B. Director | Grant or award · Restricted Stock Units | +2,500 | 2,500 | ||
| 2021-06-22 | Landis John B. Director | Grant or award · Stock Option (Right to Buy) | +11,000 | 11,000 | ||
| 2021-06-22 | DICICCO WENDY F Director | Grant or award · Restricted Stock Units | +2,500 | 2,500 | ||
| 2021-06-22 | DICICCO WENDY F Director | Grant or award · Stock Option (Right to Buy) | +11,000 | 11,000 | ||
| 2021-06-22 | ANDO GORAN Director | Grant or award · Restricted Stock Units | +2,750 | 2,750 | ||
| 2021-06-22 | ANDO GORAN Director | Grant or award · Stock Option (Right to Buy) | +12,000 | 12,000 | ||
| 2021-06-22 | Paggiarino Dario A. Chief Medical Officer | Grant or award · Restricted Stock Units | +14,900 | 14,900 | ||
| 2021-06-22 | Paggiarino Dario A. Chief Medical Officer | Grant or award · Stock Option (Right to Buy) | +60,300 | 60,300 | ||
| 2021-06-22 | Jones David Scott SVP & Chief Commercial Officer | Grant or award · Restricted Stock Units | +14,900 | 19,005 | ||
| 2021-06-22 | Jones David Scott SVP & Chief Commercial Officer | Grant or award · Stock Option (Right to Buy) | +60,300 | 60,300 | ||
| 2021-06-22 | Elston George Chief Financial Officer | Grant or award · Restricted Stock Units | +14,900 | 14,900 | ||
| 2021-06-22 | Elston George Chief Financial Officer | Grant or award · Stock Option (Right to Buy) | +60,300 | 60,300 | ||
| 2021-06-22 | Lurker Nancy President & CEO | Grant or award · Restricted Stock Units | +52,600 | 52,600 | ||
| 2021-06-22 | Lurker Nancy President & CEO | Grant or award · Stock Option (Right to Buy) | +213,700 | 213,700 | ||
| 2021-06-14 | Lurker Nancy President & CEO | Option exercise | +4,500 | 113,546 | ||
| 2021-06-14 | Lurker Nancy President & CEO | Option exercise · Restricted Stock Units | −4,500 | 0 | ||
| 2021-06-14 | Paggiarino Dario A. Chief Medical Officer | Option exercise | +1,420 | 13,012 |
Page 30 of 31 · 616 trades